Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764
- March 17, 2021 Apellis and Sobi: The New England Journal of Medicine Publishes Phase 3 PEGASUS Study Results Comparing Pegcetacoplan to Eculizumab for PNH
- March 10, 2021 Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy
- March 4, 2021 Apellis Provides Update on APL-9 for Severe COVID-19
- February 25, 2021 Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
- February 22, 2021 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
- February 18, 2021 Apellis Pharmaceuticals to Hold Fourth Quarter and Full Year 2020 Earnings Conference Call on February 25, 2021
- January 26, 2021 Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
- January 21, 2021 Apellis Pharmaceuticals to Host Investor Event on Geographic Atrophy on January 28, 2021
- January 7, 2021 Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
- January 5, 2021 Apellis Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Displaying 31 - 40 of 40